RxDoctor Payments Data

Theodore Pasquali, MD

Ophthalmology · Lakewood, CANPI 1164682738

Payments from drug & device makers

$171,236in general payments, 2019–2025

Across 68 payments — averaging $2518.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch Health US, LLC$168K
  • Glaukos Corporation$2K
  • Rxsight Inc$721
  • NEW World Medical,inc.$237
  • Tarsus Pharmaceuticals, Inc.$118
  • Harrow Eye, LLC$108
  • plus $614 from 14 others

What the payments were for

  • Consulting fees$66020%
  • Speaking & faculty fees$1,52646%
  • Food & beverage$1,11234%
  • Gifts$191%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$171,236 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$200,087
Medicare patients
562
Services billed
1,597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast39$50,697
RestasisCyclosporine21$26,317
LumiganBimatoprost35$22,740
RocklatanNetarsudil Mesylat/Latanoprost28$13,152
Prednisolone Acetate353$11,077
RhopressaNetarsudil Mesylate19$9,471
Latanoprost594$9,151
SimbrinzaBrinzolamide/Brimonidine Tart20$7,339
Ketorolac Tromethamine235$4,056
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol17$3,962
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat191$3,909
Timolol Maleate75$3,884
Ofloxacin238$2,955
Travoprost13$1,421
Brimonidine Tartrate66$965

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$80$50,69739 claims
AbbVieRestasis, Lumigan$98$49,05756 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$12$22,62347 claims
AlconSimbrinza$41$7,33920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Lakewood

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →